Therapeutic Potential of INM‐901 in Mitigating Alzheimer’s Disease Pathology: Insights from a Long‐term 5xFAD Mouse Model Study
INM-901 treatment reversed several behavioral changes, improved auditory deficits, decreased Aβ-aggregation, and modulated inflammatory and neuritogenesis markers in 5xFAD mice. These findings highlight the potential of INM-901 as a therapeutic candidate for AD and provide a basis for further evaluation in tauopathy and inflammatory neurodegenerative models.
Authors
- Michael Woudenberg
- Marjan Barazandeh (ORCID: https://orcid.org/0000-0003-3420-3669)
- James T. Kealey (ORCID: https://orcid.org/0000-0002-1227-2623)
- S. Ng
- R.K. Somvanshi (ORCID: https://orcid.org/0000-0002-7965-3068)
- Eric Hsu
- Sapna Padania
- James Craig
- Ujendra Kumar (ORCID: https://orcid.org/0000-0002-4073-7619)
- A. Sarkar (ORCID: https://orcid.org/0000-0002-2030-4525)
- Singh SNEHA
- Eric A Adams
- Shadi Madani
Institutions
- University of British Columbia (CA)
- Bay Institute (US)
- Inimex Pharmaceuticals (Canada) (CA)
- North Island College (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103609
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00